Clinical Trials Browser

Phase 2 × Mesothelioma, Malignant × Pharmacogenomic Testing × Clear all

NCT02399371 2025-06-11

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Phase 2 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural